HOME >> BIOLOGY >> NEWS
Salamanders suffer delayed effects of common herbicide

razine exposure paled in comparison to the persistent effects of atrazine that continued to cause mortality after exposure ceased, said researchers. Compared to salamanders not exposed to atrazine, survivors of the atrazine exposure had significantly lower survival 421 days after being exposed. In other words, effects of early exposure to the chemical were showing up over the long term, such that the net effect of atrazine exposure was even worse later in life than it was while the animals were being exposed.

"The biggest surprise was that it took nearly a year to detect the effects of atrazine at 4 parts per billion, which is just 1 part per billion above the maximum allowable level in drinking water set by the U.S Environmental Protection Agency," said Rohr, who presented his findings at a recent workshop organized by the U.S Geological Survey in St. Louis, Missouri.

"What this tells me is that we need to consider the long-term effects of chemicals, and that exposure to atrazine during formative stages might have permanent effects on these salamanders that increases their risk of mortality," he added.

While the mechanism by which atrazine causes elevated mortality remains unclear, Rohr says other scientists have evidence suggesting that this pesticide is an endocrine disruptor.

Such chemicals disrupt the production of hormones that are vital to normal bodily functions. Concentrations of atrazine as low as 0.1 parts per billion have been shown to cause male frogs to develop both male and female organs by altering their production of sex hormones.

Findings from Rohr's study, which was funded by the U.S Environmental Protection Agency, National Science Foundation, and the Kentucky Academy of Sciences, could have implications for global amphibian declines.

"Salamanders, and amphibians in general, are crucial to ecosystems, as both predators and prey. They can be seen as bioindicators of environmental stress and harbingers of risk
'"/>

Contact: Amitabh Avasthi
axa47@psu.edu
814-865-9481
Penn State
23-Mar-2007


Page: 1 2 3

Related biology news :

1. Better sleep may put Huntingtons disease sufferers back on track
2. Male or female factor infertility -- men suffer just the same
3. New treatment increases life time expectancy of patients suffering from advanced liver cancer
4. Coarse particulate matter in air may harm hearts of asthma sufferers, UNC study finds
5. Vaccine hope for sufferers of potentially fatal stomach bug
6. Swell gel could bring relief to back pain sufferers
7. How fish species suffer as a result of warmer waters
8. Wolves are suffering less from inbreeding than expected
9. Hope remains for Alzheimers sufferers
10. New biologic treatment for tennis elbow may replace surgery for chronic sufferers
11. Children of allergy sufferers prone to same problem

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Salamanders suffer delayed effects common herbicide

(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/3/2015)... Calif. , Aug. 3, 2015 Synaptics, ... human interface solutions, today announced that members of the ... at the Pacific Crest Global Technology Leadership Forum on ... The conference will be held at the Sonnenalp Resort ... The presentation may include forward-looking information. An audio ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its ... iLab Solutions as number 1,361 in growth for the three years through 2014. Being ... 0.1% fastest-growing privately held organizations in the country. , “We are thrilled to ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... presented new data on the relationship of genetics and hypertension at the ... Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of ... will present at the Sidoti & Company Emerging Growth ... will be held at the New York Marriott Marquis. ... will be available through the investor relations section of ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
Cached News: